Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
Featured trial
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis

A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis

  • 204 views
  • 08 Nov, 2020
  • 1 location
Featured trial
Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

  • 184 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

  • 246 views
  • 25 Mar, 2021
  • 1 location
Natalizumab and Chronic Inflammation

In this study the investigators will assess the ability of Natalizumab, a medication given to treat multiple sclerosis (MS), to restore blood brain barrier integrity and repair subtle leakages

disease or disorder
natalizumab
  • 0 views
  • 25 Mar, 2022
  • 1 location
Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab

) before and after starting Natalizumab therapy and (2) Compare BeCare-derived with clinically-derived performance metrics.

tysabri
natalizumab
natalizumab therapy
  • 0 views
  • 09 Jan, 2022
  • 1 location
Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

The purpose of this study is to generate hypotheses regarding the safety, efficacy, and immunological impact of cladribine tablets after treatment with natalizumab in patients with relapsing

relapsing multiple sclerosis
natalizumab therapy
secondary progressive multiple sclerosis
chronic progressive multiple sclerosis
cladribine
  • 0 views
  • 26 Mar, 2022
  • 1 location
Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis

The purpose of this study is to evaluate if monthly natalizumab, initiated after delivery, is effective in preventing postpartum relapses.

natalizumab
  • 22 views
  • 26 Jan, 2021
  • 1 location
Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis (NEXT-MS)

Rationale: Natalizumab is an effective drug in the treatment for relapsing remitting multiple sclerosis (RRMS) and is approved in the treatment regimen of 4-weekly 300mg natalizumab infusions

disease or disorder
progressive multifocal leukoencephalopathy
relapsing multiple sclerosis
natalizumab
  • 7 views
  • 24 Feb, 2022
  • 17 locations
Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

The purpose of this study is to assess the efficacy of autologous PBSCT versus FDA approved standard of care (i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or

betaseron
MRI
copaxone
natalizumab
avonex
  • 120 views
  • 08 Nov, 2020
  • 1 location
Inflammatory Response In Schizophrenia (IRIS)

schizophrenia, or whether this is a secondary phenomenon of no pathophysiological significance. The investigators therefore plan to test the effect of a monoclonal antibody (natalizumab) on psychotic symptoms

Accepts healthy volunteers
psychosis
psychotic symptoms
  • 0 views
  • 21 Apr, 2022
  • 1 location